AC Pharmaceuticals Co., Ltd.

The main purpose of the study is to use the pregabalin orodisintegrating tablets (150 mg) licensed by Pfizer Japan Inc. as the reference preparation and the pregabalin orodisintegrating tablets (150 mg) developed by Guangzhou Diqi Pharmaceutical Technology Co., Ltd. as the test preparation to evaluate the bioequivalence of the two preparations in the fasting and postprandial state through a single-center, randomized, open, single-dose, two-cycle, double-crossover clinical study. Secondary purpose of the study: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.